Stock listing

LSE:0QOI Newron Pharmaceuticals S.p.A. Share Price

UK listing (LSE) of Newron Pharmaceuticals S.p.A. · home listing SIX Swiss:NWRN

Follow Newron Pharmaceuticals S.p.A. into a list and get an email when it puts out news.

Share price · LSE:0QOI

8.73 CHF -0.03 (-0.3%)

Close on Oct 27, 2026

Day range
8.73 – 9.01 CHFOct 27, 2026
Volume
1,231 sharesOct 27, 2026
Market cap
211.3M CHFAt the close on Oct 27, 2026 · price × 24.20M shares outstanding
Newron Pharmaceuticals S.p.A. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
SIX Swiss:NWRN · Home9.00 CHF-0.13 (-1.4%)40,2689.209.208.809.13Close on Oct 30, 2026
Xetra:NP5€9.60 EUR+0.12 (+1.3%)1,724€9.84€10.00€9.48€9.48Close on Oct 27, 2026
LSE:0QOI8.73 CHF-0.03 (-0.3%)1,2319.019.018.738.76Close on Oct 27, 2026
Frankfurt:NP5€9.50 EUR-0.22 (-2.3%)—€9.64€9.64€9.50€9.72Close on Oct 30, 2026
Ticker
LSE:0QOI
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
CHF

What changed lately

Calls

Replays

  • Newron Pharmaceuticals (SIX Swiss: NWRN) Q4 2025 Earnings Call

    Tue, Mar 24, 2026 · 9:30 AM ET

    Watch Transcript

Latest news

Newron Completes Enrollment of Pivotal Phase 3 ENIGMA-TRS 1 Study

Oct 22, 2026

Newron presents H1 2026 results and provides corporate update

Sep 22, 2026

Newron Pharmaceuticals S p A presents H1 2026 results and provides corporate update

Sep 22, 2026

Newron Reports Subscription for EUR 5.5 Million of Shares by Investor Group as Part of Up to EUR 38 Million Total Financing to Advance Phase 3 Evenamide Program

Sep 8, 2026

Newron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Sep 3, 2026

Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)

Sep 2, 2026

Newron Provides Update Following Type A Meeting With the FDA

Jul 2, 2026

Newron Pharmaceuticals to Participate in June Investor Conferences

May 28, 2026

Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study

Apr 29, 2026

Newron Announces AGM 2026 Results

Apr 23, 2026

All Newron Pharmaceuticals S.p.A. news

Financings

  • Private placement of newly issued shares

    Sep 22, 2026

    Tranche closed: €20.5M raised

    Use of proceeds: Strengthen financial position and support continued execution of the ENIGMA-TRS Phase 3 program for evenamide

    Tranche closed Sep 8, 2026 · Tranche closed Sep 22, 2026

Read by 6ix AI from the company's releases

Decks

Newron Pharmaceuticals S.p.A. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 33 in all · newest Oct 22, 2026 · oldest 2025
Calls
1 call with a replay · 1 with a transcript · latest Mar 24, 2026
Decks
15 decks · latest Mar 24, 2026

Where Newron Pharmaceuticals S.p.A. is listed

ListingExchangeCountryCurrency
SIX Swiss:NWRN · Home listingSIX SwissSwitzerlandCHF
Xetra:NP5XetraGermanyEUR
gettex:NP5gettexGermanyEUR
LS Exchange:A0LF18LS ExchangeGermanyEUR
LSE:0QOI · This pageLSEUnited KingdomCHF
Tradegate:NP5TradegateGermanyEUR
Lang & Schwarz:A0LF18Lang & SchwarzGermanyEUR
BX Swiss:NWRNBX SwissSwitzerlandCHF
OTC:NWPHFOTCUnited StatesUSD
Frankfurt:NP5FrankfurtGermanyEUR
Aquis:NWRNZAquisUnited KingdomCHF
Stuttgart:NP5StuttgartGermanyEUR
Hamburg:NP5HamburgGermanyEUR
Dusseldorf:NP5DusseldorfGermanyEUR
Munich:NP5MunichGermanyEUR
Turquoise:NWRNZTurquoiseUnited KingdomCHF
Hanover:NP5HanoverGermanyEUR

Log in to ask 6ix AI your own questions about Newron Pharmaceuticals S.p.A.